In April 2015, Valeant acquired Salix Pharmaceuticals for about $14.5bn.
Based in North Carolina of US, Salix is a gastrointestinal market leader with a portfolio of 22 total products, including prescription brands such as Xifaxan, Uceris, Relistor, and Apriso.
In a statement related to the divestitures, Valeant said: "In accordance with its duties to shareholders and other stakeholders, management evaluates any transaction relating to core or non-core business units in accordance with the best interest of its shareholders and stakeholders.
“We are currently in discussions with third parties for various divestitures including but not limited to Salix. The discussions may or may not lead to a definitive agreement.
“Valeant does not intend to comment further on market speculation or disclose any developments unless and until it otherwise deems further disclosure is appropriate or required."
Takeda reported that it is continuously considering various options aiming to accelerate its growth focusing on prioritized therapeutic areas of gastroenterology, oncology and central nervous system plus vaccines.
Valeant produces and markets a range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.
Image: Japan’s Takeda is expected to acquire Salix gastroenterology business unit for about $10bn. Photo: courtesy of adamr / FreeDigitalPhotos.net.